Biotherapy monitoring company THERADIAG (Paris:ALTER) announced on Monday that it generated 2022 annual revenue of of EUR12.2m over the year to 31 December 2022, compared to EUR11.1m in 2021.
This is an increase of 9.7% and is reportedly in line with the company's roadmap published on 27 October 20221.
Theradiag said that it had a cash position of EUR6.4m as at 31 December 2022, compared with EUR7.1m at 31 December 2021 and EUR6.0m at 30 June 30 2022.
The growth in Theranostics activity was a result of recurring sales of i-Tracker tests, with the range having been expanded and adapted to these i-Track10 and equivalent systems. The company added that the worldwide active installed base of these systems has doubled since the end of 2021.
A specialist in in vitro diagnostics of autoimmune diseases and Theranostics, the company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca